InspireMD Inc (NSPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InspireMD Inc (NSPR) has a cash flow conversion efficiency ratio of -0.283x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.34 Million) by net assets ($43.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NSPR days of operational coverage to measure how many days the company can operate on defensive assets alone.
InspireMD Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how InspireMD Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InspireMD Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InspireMD Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kunming Longjin Pharmaceutical Co Ltd
SHE:002750
|
-0.014x |
|
NXT Energy Solutions Inc
TO:SFD
|
-0.136x |
|
Shandong Chenming Paper Holdings Limited
F:SCD1
|
0.823x |
|
Gunpoint Exploration Ltd
V:GUN
|
-0.013x |
|
Novacyt
PA:ALNOV
|
-0.141x |
|
INmune Bio Inc
NASDAQ:INMB
|
-0.214x |
|
Hudson Global Inc
NASDAQ:HSON
|
0.003x |
|
Power Solution Technologies Public Company Limited
BK:PSTC
|
-0.010x |
Annual Cash Flow Conversion Efficiency for InspireMD Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of InspireMD Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see NSPR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $55.20 Million | $-35.10 Million | -0.636x | -4.94% |
| 2024-12-31 | $36.09 Million | $-21.87 Million | -0.606x | -46.17% |
| 2023-12-31 | $39.50 Million | $-16.38 Million | -0.415x | +53.61% |
| 2022-12-31 | $17.39 Million | $-15.54 Million | -0.894x | -126.82% |
| 2021-12-31 | $33.53 Million | $-13.21 Million | -0.394x | +47.23% |
| 2020-12-31 | $12.16 Million | $-9.08 Million | -0.747x | +59.03% |
| 2019-12-31 | $5.38 Million | $-9.81 Million | -1.822x | -109.96% |
| 2018-12-31 | $8.76 Million | $-7.61 Million | -0.868x | +70.89% |
| 2017-12-31 | $2.73 Million | $-8.13 Million | -2.982x | -60.92% |
| 2016-12-31 | $4.04 Million | $-7.50 Million | -1.853x | -147.07% |
| 2015-12-31 | $-2.95 Million | $-11.60 Million | 3.936x | -43.34% |
| 2014-12-31 | $-2.79 Million | $-19.36 Million | 6.947x | +465.44% |
| 2013-12-31 | $5.42 Million | $-10.30 Million | -1.901x | -19.34% |
| 2012-12-31 | $5.39 Million | $-8.58 Million | -1.593x | 0.00% |
| 2011-12-31 | $5.39 Million | $-8.58 Million | -1.593x | -119.31% |
| 2010-12-31 | $-2.30K | $-18.98K | 8.249x | 0.00% |
| 2009-12-31 | $-2.30K | $-18.98K | 8.249x | +1774.80% |
| 2008-12-31 | $1.68K | $-825.00 | -0.493x | -- |
About InspireMD Inc
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more